Cigna updated and consolidated adalimumab coverage criteria for ophthalmic and related inflammatory indications effective 2026-03-15, clarifying FDA‑approved uses (including noninfectious uveitis and extra‑ocular disorders such as Behçet’s disease and scleritis). The policy defines distinct initial and continuation approval pathways with set durations (e.g., uveitis initial approvals 6 months, continuations 1 year; Behçet’s initial 3 months, continuations 1 year) and requires specialty prescribing or consultation. Continuation requires documented clinical benefit by objective measures (e.g., visual acuity, anterior chamber cell grade, CRP/ESR) or symptomatic improvement; biosimilars do not count as prior biologic trials for step therapy. Additional supported indications (scleritis, sterile corneal ulceration, pyoderma gangrenosum, sarcoidosis) and guideline-aligned use of TNF inhibitors for vision‑threatening or corticosteroid‑dependent disease are also specified.
March 15, 2026 Revision: Consolidated Adalimumab Ophthalmology Criteria
This revision (effective 2026-03-15) clarifies and consolidates coverage criteria for adalimumab products across multiple ophthalmic and related inflammatory indications within Cigna's IP0652 Drug Coverage Policy under MDC 02: Ophthalmology. The document explicitly restates FDA‑approved uses including uveitis (noninfectious intermediate, posterior, and panuveitis) and several extra‑ocular inflammatory disorders (e.g., Behcet's disease, scleritis, and pyoderma gangrenosum).
The update organizes initial versus continuation (established therapy) approval pathways with defined approval durations (for example, initial therapy approvals for uveitis are 6 months, and continuation approvals are 1 year), and specifies objective measures or symptom improvement that must be documented for continuation determinations.
Uveitis Coverage Criteria and Approval Durations
For uveitis (including other posterior uveitides and panuveitis syndromes) the policy defines two distinct approval pathways. Initial therapy: approve for 6 months if the patient is ≥ 2 years old, has tried at least one of periocular, intraocular, or systemic corticosteroids or immunosuppressives (a prior biologic other than the requested agent also counts), and the medication is prescribed by or in consultation with an ophthalmologist. Continuation (currently receiving an adalimumab product): approve for 1 year if the patient has been on therapy at least 6 months and demonstrates benefit either by objective measure (examples include best‑corrected visual acuity, anterior chamber cell grade, vitreous haze grade, or assessment of lesions) or symptomatic improvement (e.g., decreased eye pain, redness, photophobia, blurred vision, or improved visual acuity).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.